2fom › Citations

Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.

Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U
Nat Struct Mol Biol 13 372-3 (2006)
Cited: 315 times
EuropePMC logo PMID: 16532006

Abstract

The replication of flaviviruses requires the correct processing of their polyprotein by the viral NS3 protease (NS3pro). Essential for the activation of NS3pro is a 47-residue region of NS2B. Here we report the crystal structures of a dengue NS2B-NS3pro complex and a West Nile virus NS2B-NS3pro complex with a substrate-based inhibitor. These structures identify key residues for NS3pro substrate recognition and clarify the mechanism of NS3pro activation.

Reviews - 2fom mentioned but not cited (13)

  1. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M. Antiviral Res 87 125-148 (2010)
  2. Structure-based discovery of dengue virus protease inhibitors. Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. Antiviral Res 82 110-114 (2009)
  3. Focus on flaviviruses: current and future drug targets. Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM. Future Med Chem 1 327-344 (2009)
  4. Proteases from dengue, West Nile and Zika viruses as drug targets. Nitsche C. Biophys Rev 11 157-165 (2019)
  5. Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery. Li Q, Kang C. Int J Mol Sci 21 E5262 (2020)
  6. Strategies Towards Protease Inhibitors for Emerging Flaviviruses. Nitsche C. Adv Exp Med Biol 1062 175-186 (2018)
  7. The expanding diversity of serine hydrolases. Botos I, Wlodawer A. Curr Opin Struct Biol 17 683-690 (2007)
  8. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Samrat SK, Xu J, Li Z, Zhou J, Li H. Pathogens 11 293 (2022)
  9. Insights into Structures and Dynamics of Flavivirus Proteases from NMR Studies. Li Q, Kang C. Int J Mol Sci 21 E2527 (2020)
  10. A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases. Murtuja S, Shilkar D, Sarkar B, Sinha BN, Jayaprakash V. Bioorg Med Chem 49 116415 (2021)
  11. Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach. Norshidah H, Leow CH, Ezleen KE, Wahab HA, Vignesh R, Rasul A, Lai NS. Front Cell Infect Microbiol 13 1061937 (2023)
  12. Inhibitory Potential of Chromene Derivatives on Structural and Non-Structural Proteins of Dengue Virus. Dharmapalan BT, Biswas R, Sankaran S, Venkidasamy B, Thiruvengadam M, George G, Rebezov M, Zengin G, Gallo M, Montesano D, Naviglio D, Shariati MA. Viruses 14 2656 (2022)
  13. The Future of Carica papaya Leaf Extract as an Herbal Medicine Product. Hariono M, Julianus J, Djunarko I, Hidayat I, Adelya L, Indayani F, Auw Z, Namba G, Hariyono P. Molecules 26 6922 (2021)

Articles - 2fom mentioned but not cited (73)

  1. Crystal structure of the NS3 protease-helicase from dengue virus. Luo D, Xu T, Hunke C, Grüber G, Vasudevan SG, Lescar J. J Virol 82 173-183 (2008)
  2. Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. Assenberg R, Mastrangelo E, Walter TS, Verma A, Milani M, Owens RJ, Stuart DI, Grimes JM, Mancini EJ. J Virol 83 12895-12906 (2009)
  3. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. Luo D, Wei N, Doan DN, Paradkar PN, Chong Y, Davidson AD, Kotaka M, Lescar J, Vasudevan SG. J Biol Chem 285 18817-18827 (2010)
  4. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease. Brecher M, Li Z, Liu B, Zhang J, Koetzner CA, Alifarag A, Jones SA, Lin Q, Kramer LD, Li H. PLoS Pathog 13 e1006411 (2017)
  5. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Lee H, Ren J, Nocadello S, Rice AJ, Ojeda I, Light S, Minasov G, Vargas J, Nagarathnam D, Anderson WF, Johnson ME. Antiviral Res 139 49-58 (2017)
  6. NMR analysis of a novel enzymatically active unlinked dengue NS2B-NS3 protease complex. Kim YM, Gayen S, Kang C, Joy J, Huang Q, Chen AS, Wee JL, Ang MJ, Lim HA, Hung AW, Li R, Noble CG, Lee le T, Yip A, Wang QY, Chia CS, Hill J, Shi PY, Keller TH. J Biol Chem 288 12891-12900 (2013)
  7. Allosteric inhibition of the NS2B-NS3 protease from dengue virus. Yildiz M, Ghosh S, Bell JA, Sherman W, Hardy JA. ACS Chem Biol 8 2744-2752 (2013)
  8. Dengue virus subverts the interferon induction pathway via NS2B/3 protease-IκB kinase epsilon interaction. Angleró-Rodríguez YI, Pantoja P, Sariol CA. Clin Vaccine Immunol 21 29-38 (2014)
  9. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. Tahir Ul Qamar M, Maryam A, Muneer I, Xing F, Ashfaq UA, Khan FA, Anwar F, Geesi MH, Khalid RR, Rauf SA, Siddiqi AR. Sci Rep 9 1433 (2019)
  10. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease. Su XC, Ozawa K, Qi R, Vasudevan SG, Lim SP, Otting G. PLoS Negl Trop Dis 3 e561 (2009)
  11. Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly. Senthilvel P, Lavanya P, Kumar KM, Swetha R, Anitha P, Bag S, Sarveswari S, Vijayakumar V, Ramaiah S, Anbarasu A. Bioinformation 9 889-895 (2013)
  12. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P. J Virol 84 3059-3067 (2010)
  13. Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease. Bharadwaj S, Lee KE, Dwivedi VD, Yadava U, Panwar A, Lucas SJ, Pandey A, Kang SG. Sci Rep 9 19059 (2019)
  14. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Tomlinson SM, Watowich SJ. Antiviral Res 89 127-135 (2011)
  15. Boesenbergia rotunda: From Ethnomedicine to Drug Discovery. Eng-Chong T, Yean-Kee L, Chin-Fei C, Choon-Han H, Sher-Ming W, Li-Ping CT, Gen-Teck F, Khalid N, Abd Rahman N, Karsani SA, Othman S, Othman R, Yusof R. Evid Based Complement Alternat Med 2012 473637 (2012)
  16. Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. Shiryaev SA, Ratnikov BI, Aleshin AE, Kozlov IA, Nelson NA, Lebl M, Smith JW, Liddington RC, Strongin AY. J Virol 81 4501-4509 (2007)
  17. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Lai H, Dou D, Aravapalli S, Teramoto T, Lushington GH, Mwania TM, Alliston KR, Eichhorn DM, Padmanabhan R, Groutas WC. Bioorg Med Chem 21 102-113 (2013)
  18. Mechanism of NS2B-mediated activation of NS3pro in dengue virus: molecular dynamics simulations and bioassays. Zuo Z, Liew OW, Chen G, Chong PC, Lee SH, Chen K, Jiang H, Puah CM, Zhu W. J Virol 83 1060-1070 (2009)
  19. JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo. Li Z, Xu J, Lang Y, Fan X, Kuo L, D'Brant L, Hu S, Samrat SK, Trudeau N, Tharappel AM, Rugenstein N, Koetzner CA, Zhang J, Chen H, Kramer LD, Butler D, Zhang QY, Zhou J, Li H. ACS Infect Dis 6 2616-2628 (2020)
  20. NMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional Dynamics. Gupta G, Lim L, Song J. PLoS One 10 e0134823 (2015)
  21. Design of new competitive dengue NS2B/NS3 protease inhibitors-a computational approach. Frimayanti N, Chee CF, Zain SM, Rahman NA. Int J Mol Sci 12 1089-1100 (2011)
  22. A Proline-Rich N-Terminal Region of the Dengue Virus NS3 Is Crucial for Infectious Particle Production. Gebhard LG, Iglesias NG, Byk LA, Filomatori CV, De Maio FA, Gamarnik AV. J Virol 90 5451-5461 (2016)
  23. Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Tambunan US, Alamudi S. Bioinformation 5 250-254 (2010)
  24. Discovery of antiviral molecules for dengue: In silico search and biological evaluation. Cabarcas-Montalvo M, Maldonado-Rojas W, Montes-Grajales D, Bertel-Sevilla A, Wagner-Döbler I, Sztajer H, Reck M, Flechas-Alarcon M, Ocazionez R, Olivero-Verbel J. Eur J Med Chem 110 87-97 (2016)
  25. A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture. Raut R, Beesetti H, Tyagi P, Khanna I, Jain SK, Jeankumar VU, Yogeeswari P, Sriram D, Swaminathan S. Virol J 12 16 (2015)
  26. Effects of cocktail of four local Malaysian medicinal plants (Phyllanthus spp.) against dengue virus 2. Lee SH, Tang YQ, Rathkrishnan A, Wang SM, Ong KC, Manikam R, Payne BJ, Jaganath IB, Sekaran SD. BMC Complement Altern Med 13 192 (2013)
  27. Capturing conformational States in proteins using sparse paramagnetic NMR data. Pilla KB, Leman JK, Otting G, Huber T. PLoS One 10 e0127053 (2015)
  28. Curcumin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting Its Active Conformation. Lim L, Dang M, Roy A, Kang J, Song J. ACS Omega 5 25677-25686 (2020)
  29. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease. Sarwar MW, Riaz A, Dilshad SMR, Al-Qahtani A, Nawaz-Ul-Rehman MS, Mubin M. BMC Struct Biol 18 6 (2018)
  30. Activation of the West Nile virus NS3 protease: molecular dynamics evidence for a conformational selection mechanism. Ekonomiuk D, Caflisch A. Protein Sci 18 1003-1011 (2009)
  31. Computer Aided Screening of Phytochemicals from Garcinia against the Dengue NS2B/NS3 Protease. Qamar TU, Mumtaz A, Ashfaq UA, Azhar S, Fatima T, Hassan M, Hussain SS, Akram W, Idrees S. Bioinformation 10 115-118 (2014)
  32. Dibromopinocembrin and Dibromopinostrobin Are Potential Anti-Dengue Leads with Mild Animal Toxicity. Boonyasuppayakorn S, Saelee T, Visitchanakun P, Leelahavanichkul A, Hengphasatporn K, Shigeta Y, Huynh TNT, Chu JJH, Rungrotmongkol T, Chavasiri W. Molecules 25 E4154 (2020)
  33. Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities. Pelliccia S, Wu YH, Coluccia A, La Regina G, Tseng CK, Famiglini V, Masci D, Hiscott J, Lee JC, Silvestri R. J Enzyme Inhib Med Chem 32 1091-1101 (2017)
  34. Structural and functional parameters of the flaviviral protease: a promising antiviral drug target. Shiryaev SA, Strongin AY. Future Virol 5 593-606 (2010)
  35. A Computational Approach Applied to the Study of Potential Allosteric Inhibitors Protease NS2B/NS3 from Dengue Virus. Costa RAD, Rocha JAPD, Pinheiro AS, Costa ADSSD, Rocha ECMD, Silva RC, Gonçalves ADS, Santos CBR, Brasil DDSB. Molecules 27 4118 (2022)
  36. Evaluation of the Leaf Essential Oil from Artemisia vulgaris and Its Larvicidal and Repellent Activity against Dengue Fever Vector Aedes aegypti-An Experimental and Molecular Docking Investigation. Balasubramani S, Sabapathi G, Moola AK, Solomon RV, Venuvanalingam P, Bollipo Diana RK. ACS Omega 3 15657-15665 (2018)
  37. The Utility of the HSAB Principle via the Fukui Function in Biological Systems. Faver J, Merz KM. J Chem Theory Comput 6 548-559 (2010)
  38. 4-Thiazolidinone coumarin derivatives as two-component NS2B/NS3 DENV flavivirus serine protease inhibitors: synthesis, molecular docking, biological evaluation and structure-activity relationship studies. Yusufzai SK, Osman H, Khan MS, Abd Razik BM, Ezzat MO, Mohamad S, Sulaiman O, Gansau JA, Parumasivam T. Chem Cent J 12 69 (2018)
  39. Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3. Salaemae W, Junaid M, Angsuthanasombat C, Katzenmeier G. J Biomed Sci 17 68 (2010)
  40. 3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors. Osman H, Idris NH, Kamarulzaman EE, Wahab HA, Hassan MZ. Acta Pharm Sin B 7 479-484 (2017)
  41. Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking. Idrees S, Ashfaq UA. Asian Pac J Trop Med 7 513-516 (2014)
  42. Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage. Coluccia A, Puxeddu M, Nalli M, Wei CK, Wu YH, Mastrangelo E, Elamin T, Tarantino D, Bugert JJ, Schreiner B, Nolte J, Schwarze F, La Regina G, Lee JC, Silvestri R. ACS Med Chem Lett 11 1869-1874 (2020)
  43. Ligand Accessibility Insights to the Dengue Virus NS3-NS2B Protease Assessed by Long-Timescale Molecular Dynamics Simulations. Kronenberger T, Sá Magalhães Serafim M, Kumar Tonduru A, Gonçalves Maltarollo V, Poso A. ChemMedChem 16 2524-2534 (2021)
  44. New binding site conformations of the dengue virus NS3 protease accessed by molecular dynamics simulation. de Almeida H, Bastos IM, Ribeiro BM, Maigret B, Santana JM. PLoS One 8 e72402 (2013)
  45. Structural features of NS3 of Dengue virus serotypes 2 and 4 in solution and insight into RNA binding and the inhibitory role of quercetin. Pan A, Saw WG, Subramanian Manimekalai MS, Grüber A, Joon S, Matsui T, Weiss TM, Grüber G. Acta Crystallogr D Struct Biol 73 402-419 (2017)
  46. Using bioinformatics tools for the discovery of Dengue RNA-dependent RNA polymerase inhibitors. Nncube NB, Ramharack P, Soliman MES. PeerJ 6 e5068 (2018)
  47. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease. Velmurugan D, Mythily U, Rao K. Protein Pept Lett 21 815-827 (2014)
  48. Microwave Optimized Synthesis of N-(adamantan-1-yl)-4-[(adamantan-1-yl)-sulfamoyl]benzamide and Its Derivatives for Anti-Dengue Virus Activity. Joubert J, Foxen EB, Malan SF. Molecules 23 E1678 (2018)
  49. Analysis of binding properties and specificity through identification of the interface forming residues (IFR) for serine proteases in silico docked to different inhibitors. Ribeiro C, Togawa RC, Neshich IA, Mazoni I, Mancini AL, Minardi RC, da Silveira CH, Jardine JG, Santoro MM, Neshich G. BMC Struct Biol 10 36 (2010)
  50. Essential Oils from Colombian Plants: Antiviral Potential against Dengue Virus Based on Chemical Composition, In Vitro and In Silico Analyses. Silva-Trujillo L, Quintero-Rueda E, Stashenko EE, Conde-Ocazionez S, Rondón-Villarreal P, Ocazionez RE. Molecules 27 6844 (2022)
  51. Evaluation of Melongosides as Potential Inhibitors of NS2B-NS3 Activator-Protease of Dengue Virus (Serotype 2) by Using Molecular Docking and Dynamics Simulation Approach. Biswas P, Hany Rumi O, Ahmed Khan D, Ahmed MN, Nahar N, Jahan R, Hasan Zilani MN, Paul TK, Hasan A, Bondhon TA, Jannat K, Hasan MN, Rahmatullah M. J Trop Med 2022 7111786 (2022)
  52. 'Hot' macromolecular crystals. Koclega KD, Chruszcz M, Zimmerman MD, Bujacz G, Minor W. Cryst Growth Des 10 580 (2009)
  53. In Silico Screening, Alanine Mutation, and DFT Approaches for Identification of NS2B/NS3 Protease Inhibitors. Balajee R, Srinivasadesikan V, Sakthivadivel M, Gunasekaran P. Biochem Res Int 2016 7264080 (2016)
  54. Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study. Shimu MSS, Mahmud S, Tallei TE, Sami SA, Adam AA, Acharjee UK, Paul GK, Emran TB, Zaman S, Uddin MS, Saleh MA, Alshehri S, Ghoneim MM, Alruwali M, Obaidullah AJ, Jui NR, Kim J, Kim B. Molecules 27 653 (2022)
  55. Product release is rate-limiting for catalytic processing by the Dengue virus protease. Shannon AE, Pedroso MM, Chappell KJ, Watterson D, Liebscher S, Kok WM, Fairlie DP, Schenk G, Young PR. Sci Rep 6 37539 (2016)
  56. In Silico Analysis of Dengue Virus Serotype 2 Mutations Detected at the Intrahost Level in Patients with Different Clinical Outcomes. Torres MC, Martins Karl AL, Müller Pereira da Silva M, Dardenne LE, Bispo de Filippis AM. Microbiol Spectr 9 e0025621 (2021)
  57. 1H, 13C and 15N resonance assignment of backbone and IVL-methyl side chain of the S135A mutant NS3pro/NS2B protein of Dengue II virus reveals unique secondary structure features in solution. Agback P, Lesovoy DM, Han X, Sun R, Sandalova T, Agback T, Achour A, Orekhov VY. Biomol NMR Assign 16 135-145 (2022)
  58. Design & discovery of small molecule COVID-19 inhibitor via dual approach based virtual screening and molecular simulation studies. Aljarba NH, Hasnain MS, Bin-Meferij MM, Alkahtani S. J King Saud Univ Sci 34 101867 (2022)
  59. Lichen-Derived Diffractaic Acid Inhibited Dengue Virus Replication in a Cell-Based System. Loeanurit N, Tuong TL, Nguyen VK, Vibulakhaophan V, Hengphasatporn K, Shigeta Y, Ho SX, Chu JJH, Rungrotmongkol T, Chavasiri W, Boonyasuppayakorn S. Molecules 28 974 (2023)
  60. Seawater fungi-derived compound screening to identify novel small molecules against dengue virus NS5 methyltransferase and NS2B/NS3 protease. Hasan M, Mia MM, Munna SU, Talha MMH, Das K. Inform Med Unlocked 30 100932 (2022)
  61. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies. Purohit P, Sahoo S, Panda M, Sahoo PS, Meher BR. J Mol Model 28 365 (2022)
  62. In silico testing of flavonoids as potential inhibitors of protease and helicase domains of dengue and Zika viruses. Cruz-Arreola O, Orduña-Diaz A, Domínguez F, Reyes-Leyva J, Vallejo-Ruiz V, Domínguez-Ramírez L, Santos-López G. PeerJ 10 e13650 (2022)
  63. Biocidal action, characterization, and molecular docking of Mentha piperita (Lamiaceae) leaves extract against Culex quinquefasciatus (Diptera: Culicidae) larvae. Iqbal A, Qureshi NA, Alhewairini SS, Shaheen N, Hamid A, Qureshi MZ. PLoS One 17 e0270219 (2022)
  64. Boroleucine-Derived Covalent Inhibitors of the ZIKV Protease. Braun NJ, Huber S, Schmacke LC, Heine A, Steinmetzer T. ChemMedChem 18 e202200336 (2023)
  65. Dengue virus protease activity modulated by dynamics of protease cofactor. Lee WHK, Liu W, Fan JS, Yang D. Biophys J 120 2444-2453 (2021)
  66. Ligand-based pharmacophore modeling and QSAR approach to identify potential dengue protease inhibitors. Poola AA, Prabhu PS, Murthy TPK, Murahari M, Krishna S, Samantaray M, Ramaswamy A. Front Mol Biosci 10 1106128 (2023)
  67. Papaya Leaf Extracts as Potential Dengue Treatment: An In-Silico Study. Madushanka A, Verma N, Freindorf M, Kraka E. Int J Mol Sci 23 12310 (2022)
  68. Antiviral Activities of Streptomyces KSF 103 Methanolic Extracts against Dengue Virus Type-2. Zulkifli N, Khairat JE, Azman AS, Baharudin NM, Malek NA, Zainal Abidin SA, AbuBakar S, Hassandarvish P. Viruses 15 1773 (2023)
  69. Combined NMR and molecular dynamics conformational filter identifies unambiguously dynamic ensembles of Dengue protease NS2B/NS3pro. Agback T, Lesovoy D, Han X, Lomzov A, Sun R, Sandalova T, Orekhov VY, Achour A, Agback P. Commun Biol 6 1193 (2023)
  70. Dataset on biochemical inhibiting activities of selected phytochemicals in Azadirachta indica L as potential NS2B-NS3 proteases inhibitors. Oyebamiji AK, Akintelu SA, Akande IO, Aworinde HO, Adepegba OA, Akintayo ET, Akintayo CO, Semire B, Babalola JO. Data Brief 48 109162 (2023)
  71. Dual function of Zika virus NS2B-NS3 protease. Shiryaev SA, Cieplak P, Cheltsov A, Liddington RC, Terskikh AV. PLoS Pathog 19 e1011795 (2023)
  72. Exploring the inhibitory potential of Nigella sativa against dengue virus NS2B/NS3 protease and NS5 polymerase using computational approaches. Mukhtar M, Khan HA, Zaidi NUSS. RSC Adv 13 18306-18322 (2023)
  73. Structural Modifications Introduced by NS2B Cofactor Binding to the NS3 Protease of the Kyasanur Forest Disease Virus. Kandagalla S, Kumbar B, Novak J. Int J Mol Sci 24 10907 (2023)


Reviews citing this publication (53)

  1. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Weaver SC, Vasilakis N. Infect Genet Evol 9 523-540 (2009)
  2. Structural proteomics of dengue virus. Perera R, Kuhn RJ. Curr Opin Microbiol 11 369-377 (2008)
  3. Ten years of dengue drug discovery: progress and prospects. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. Antiviral Res 100 500-519 (2013)
  4. Molecular targets for flavivirus drug discovery. Sampath A, Padmanabhan R. Antiviral Res 81 6-15 (2009)
  5. Strategies for development of Dengue virus inhibitors. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. Antiviral Res 85 450-462 (2010)
  6. Biochemistry and Molecular Biology of Flaviviruses. Barrows NJ, Campos RK, Liao KC, Prasanth KR, Soto-Acosta R, Yeh SC, Schott-Lerner G, Pompon J, Sessions OM, Bradrick SS, Garcia-Blanco MA. Chem Rev 118 4448-4482 (2018)
  7. A practical view of 'druggability'. Keller TH, Pichota A, Yin Z. Curr Opin Chem Biol 10 357-361 (2006)
  8. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Luo D, Vasudevan SG, Lescar J. Antiviral Res 118 148-158 (2015)
  9. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Boldescu V, Behnam MAM, Vasilakis N, Klein CD. Nat Rev Drug Discov 16 565-586 (2017)
  10. Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. de Azeredo EL, Monteiro RQ, de-Oliveira Pinto LM. Mediators Inflamm 2015 313842 (2015)
  11. Treatment of yellow fever. Monath TP. Antiviral Res 78 116-124 (2008)
  12. Replication cycle and molecular biology of the West Nile virus. Brinton MA. Viruses 6 13-53 (2013)
  13. Structural Biology of the Zika Virus. Shi Y, Gao GF. Trends Biochem Sci 42 443-456 (2017)
  14. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Noble CG, Shi PY. Antiviral Res 96 115-126 (2012)
  15. Viral protease inhibitors. Anderson J, Schiffer C, Lee SK, Swanstrom R. Handb Exp Pharmacol 85-110 (2009)
  16. RNA-virus proteases counteracting host innate immunity. Lei J, Lei J, Hilgenfeld R. FEBS Lett 591 3190-3210 (2017)
  17. The role of viral persistence in flavivirus biology. Mlera L, Melik W, Bloom ME. Pathog Dis 71 137-163 (2014)
  18. Zika Virus Protease: An Antiviral Drug Target. Kang C, Keller TH, Luo D. Trends Microbiol 25 797-808 (2017)
  19. Tick-Borne Encephalitis Virus: A Structural View. Pulkkinen LIA, Butcher SJ, Anastasina M. Viruses 10 E350 (2018)
  20. The flavivirus protease as a target for drug discovery. Brecher M, Zhang J, Li H. Virol Sin 28 326-336 (2013)
  21. Recent Developments in Recombinant Protein-Based Dengue Vaccines. Tripathi NK, Shrivastava A. Front Immunol 9 1919 (2018)
  22. Organization of the Flavivirus RNA replicase complex. Brand C, Bisaillon M, Geiss BJ. Wiley Interdiscip Rev RNA 8 (2017)
  23. Antiviral Agents in Development for Zika Virus Infections. Baz M, Boivin G. Pharmaceuticals (Basel) 12 E101 (2019)
  24. Functional interplay among the flavivirus NS3 protease, helicase, and cofactors. Li K, Phoo WW, Luo D. Virol Sin 29 74-85 (2014)
  25. West Nile virus drug discovery. Lim SP, Shi PY. Viruses 5 2977-3006 (2013)
  26. Regulation of flavivirus RNA synthesis and capping. Saeedi BJ, Geiss BJ. Wiley Interdiscip Rev RNA 4 723-735 (2013)
  27. Opportunities for structure-based design of protease-directed drugs. Mittl PR, Grütter MG. Curr Opin Struct Biol 16 769-775 (2006)
  28. Biological characteristics of dengue virus and potential targets for drug design. Qi RF, Zhang L, Chi CW. Acta Biochim Biophys Sin (Shanghai) 40 91-101 (2008)
  29. Development of Small-Molecule Inhibitors Against Zika Virus Infection. Wang L, Liang R, Gao Y, Li Y, Deng X, Xiang R, Zhang Y, Ying T, Jiang S, Yu F. Front Microbiol 10 2725 (2019)
  30. New developments in flavivirus drug discovery. Kok WM. Expert Opin Drug Discov 11 433-445 (2016)
  31. Molecular Insights into the Flavivirus Replication Complex. van den Elsen K, Quek JP, Luo D. Viruses 13 956 (2021)
  32. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Bhakat S, Bhakat S, Karubiu W, Jayaprakash V, Soliman ME. Eur J Med Chem 87 677-702 (2014)
  33. Therapeutic Approaches for Zika Virus Infection of the Nervous System. Abrams RPM, Solis J, Nath A. Neurotherapeutics 14 1027-1048 (2017)
  34. Compartmentalized replication organelle of flavivirus at the ER and the factors involved. Ci Y, Shi L. Cell Mol Life Sci 78 4939-4954 (2021)
  35. Important advances in the field of anti-dengue virus research. Julander JG, Perry ST, Shresta S. Antivir Chem Chemother 21 105-116 (2011)
  36. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review. Wahaab A, Mustafa BE, Hameed M, Stevenson NJ, Anwar MN, Liu K, Wei J, Qiu Y, Ma Z. Viruses 14 44 (2021)
  37. Structurally- and dynamically-driven allostery of the chymotrypsin-like proteases of SARS, Dengue and Zika viruses. Lim L, Gupta G, Roy A, Kang J, Srivastava S, Shi J, Song J. Prog Biophys Mol Biol 143 52-66 (2019)
  38. Structure-guided paradigm shifts in flavivirus assembly and maturation mechanisms. Nicholls CMR, Sevvana M, Kuhn RJ. Adv Virus Res 108 33-83 (2020)
  39. Flavivirus: From Structure to Therapeutics Development. Zhao R, Wang M, Cao J, Shen J, Zhou X, Wang D, Cao J. Life (Basel) 11 615 (2021)
  40. Viral proteases as therapeutic targets. Majerová T, Konvalinka J. Mol Aspects Med 88 101159 (2022)
  41. Structure and Dynamics of Zika Virus Protease and Its Insights into Inhibitor Design. Li Q, Kang C. Biomedicines 9 1044 (2021)
  42. Structures and Dynamics of Dengue Virus Nonstructural Membrane Proteins. Li Q, Kang C. Membranes (Basel) 12 231 (2022)
  43. Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection. Song W, Zhang H, Zhang Y, Li R, Han Y, Lin Y, Jiang J. Front Med 15 404-415 (2021)
  44. Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds. Leonel CA, Lima WG, Dos Santos M, Ferraz AC, Taranto AG, de Magalhães JC, Dos Santos LL, Ferreira JMS. Arch Virol 163 575-586 (2018)
  45. Surgical Strikes on Host Defenses: Role of the Viral Protease Activity in Innate Immune Antagonism. Chin CV, Saeed M. Pathogens 11 522 (2022)
  46. A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika. Sundar S, Piramanayagam S, Natarajan J. Virus Genes 58 151-171 (2022)
  47. Flavivirus proteases: The viral Achilles heel to prevent future pandemics. Teramoto T, Choi KH, Padmanabhan R. Antiviral Res 210 105516 (2023)
  48. Targeting the protease of West Nile virus. Voss S, Nitsche C. RSC Med Chem 12 1262-1272 (2021)
  49. Analyzing the Geometry and Dynamics of Viral Structures: A Review of Computational Approaches Based on Alpha Shape Theory, Normal Mode Analysis, and Poisson-Boltzmann Theories. Hsieh YC, Delarue M, Orland H, Koehl P. Viruses 15 1366 (2023)
  50. Contributions of Ubiquitin and Ubiquitination to Flaviviral Antagonism of Type I IFN. Hay-McCullough E, Morrison J. Viruses 13 763 (2021)
  51. Covalent Antiviral Agents. Mirzaie S, Abdi F, GhavamiNejad A, Lu B, Wu XY. Adv Exp Med Biol 1322 285-312 (2021)
  52. Small molecule inhibitors of West Nile virus. Elseginy SA, Massarotti A, Nawwar GA, Amin KM, Brancale A. Antivir Chem Chemother 23 179-187 (2014)
  53. Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview. Diani E, Lagni A, Lotti V, Tonon E, Cecchetto R, Gibellini D. Microorganisms 11 2427 (2023)

Articles citing this publication (176)

  1. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, Vasudevan SG, Lescar J. J Virol 81 4753-4765 (2007)
  2. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Lei J, Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R. Science 353 503-505 (2016)
  3. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Jo S, Kim H, Kim S, Shin DH, Kim MS. Chem Biol Drug Des 94 2023-2030 (2019)
  4. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Aleshin AE, Shiryaev SA, Strongin AY, Liddington RC. Protein Sci 16 795-806 (2007)
  5. Ligand-bound structures of the dengue virus protease reveal the active conformation. Noble CG, Seh CC, Chao AT, Shi PY. J Virol 86 438-446 (2012)
  6. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Phoo WW, Li Y, Zhang Z, Lee MY, Loh YR, Tan YB, Ng EY, Lescar J, Kang C, Luo D. Nat Commun 7 13410 (2016)
  7. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. Robin G, Chappell K, Stoermer MJ, Hu SH, Young PR, Fairlie DP, Martin JL. J Mol Biol 385 1568-1577 (2009)
  8. Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. Patkar CG, Kuhn RJ. J Virol 82 3342-3352 (2008)
  9. Crystal structure of unlinked NS2B-NS3 protease from Zika virus. Zhang Z, Li Y, Loh YR, Phoo WW, Hung AW, Kang C, Luo D. Science 354 1597-1600 (2016)
  10. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. Lindenbach BD, Prágai BM, Montserret R, Beran RK, Pyle AM, Penin F, Rice CM. J Virol 81 8905-8918 (2007)
  11. Coumarin: An emerging antiviral agent. Mishra S, Pandey A, Manvati S. Heliyon 6 e03217 (2020)
  12. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R. Antimicrob Agents Chemother 52 3385-3393 (2008)
  13. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Johnston PA, Phillips J, Shun TY, Shinde S, Lazo JS, Huryn DM, Myers MC, Ratnikov BI, Smith JW, Su Y, Dahl R, Cosford ND, Shiryaev SA, Strongin AY. Assay Drug Dev Technol 5 737-750 (2007)
  14. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Shiryaev SA, Farhy C, Pinto A, Huang CT, Simonetti N, Elong Ngono A, Dewing A, Shresta S, Pinkerton AB, Cieplak P, Strongin AY, Terskikh AV. Antiviral Res 143 218-229 (2017)
  15. Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies. de Sousa LR, Wu H, Nebo L, Fernandes JB, da Silva MF, Kiefer W, Kanitz M, Bodem J, Diederich WE, Schirmeister T, Vieira PC. Bioorg Med Chem 23 466-470 (2015)
  16. Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein. Mastrangelo E, Milani M, Bollati M, Selisko B, Peyrane F, Pandini V, Sorrentino G, Canard B, Konarev PV, Svergun DI, de Lamballerie X, Coutard B, Khromykh AA, Bolognesi M. J Mol Biol 372 444-455 (2007)
  17. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A. Antimicrob Agents Chemother 55 229-238 (2011)
  18. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Bodenreider C, Beer D, Keller TH, Sonntag S, Wen D, Yap L, Yau YH, Shochat SG, Huang D, Zhou T, Caflisch A, Su XC, Ozawa K, Otting G, Vasudevan SG, Lescar J, Lim SP. Anal Biochem 395 195-204 (2009)
  19. Inhibitory effect of doxycycline against dengue virus replication in vitro. Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R. Arch Virol 159 711-718 (2014)
  20. Characterization of the West Nile virus protease substrate specificity and inhibitors. Mueller NH, Yon C, Ganesh VK, Padmanabhan R. Int J Biochem Cell Biol 39 606-614 (2007)
  21. Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. Yao Y, Huo T, Lin YL, Nie S, Wu F, Hua Y, Wu J, Kneubehl AR, Vogt MB, Rico-Hesse R, Song Y. J Am Chem Soc 141 6832-6836 (2019)
  22. Multiple-site labeling of proteins with unnatural amino acids. Loscha KV, Herlt AJ, Qi R, Huber T, Ozawa K, Otting G. Angew Chem Int Ed Engl 51 2243-2246 (2012)
  23. NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus. Shiryaev SA, Chernov AV, Aleshin AE, Shiryaeva TN, Strongin AY. J Gen Virol 90 2081-2085 (2009)
  24. Novel ATP-independent RNA annealing activity of the dengue virus NS3 helicase. Gebhard LG, Kaufman SB, Gamarnik AV. PLoS One 7 e36244 (2012)
  25. DEPTH: a web server to compute depth and predict small-molecule binding cavities in proteins. Tan KP, Varadarajan R, Madhusudhan MS. Nucleic Acids Res 39 W242-8 (2011)
  26. Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease. Kumar A, Liang B, Aarthy M, Singh SK, Garg N, Mysorekar IU, Giri R. ACS Omega 3 18132-18141 (2018)
  27. Cell-free transcription/translation from PCR-amplified DNA for high-throughput NMR studies. Wu PS, Ozawa K, Lim SP, Vasudevan SG, Dixon NE, Otting G. Angew Chem Int Ed Engl 46 3356-3358 (2007)
  28. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA, Yusof R. BMC Infect Dis 12 314 (2012)
  29. Structural Dynamics of Zika Virus NS2B-NS3 Protease Binding to Dipeptide Inhibitors. Li Y, Zhang Z, Phoo WW, Loh YR, Wang W, Liu S, Chen MW, Hung AW, Keller TH, Luo D, Kang C. Structure 25 1242-1250.e3 (2017)
  30. Intrinsically Disordered Side of the Zika Virus Proteome. Giri R, Kumar D, Sharma N, Uversky VN. Front Cell Infect Microbiol 6 144 (2016)
  31. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. Hammamy MZ, Haase C, Hammami M, Hilgenfeld R, Steinmetzer T. ChemMedChem 8 231-241 (2013)
  32. Mutations in the NS2B and NS3 genes affect mouse neuroinvasiveness of a Western European field strain of tick-borne encephalitis virus. Růzek D, Gritsun TS, Forrester NL, Gould EA, Kopecký J, Golovchenko M, Rudenko N, Grubhoffer L. Virology 374 249-255 (2008)
  33. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Shiryaev SA, Kozlov IA, Ratnikov BI, Smith JW, Lebl M, Strongin AY. Biochem J 401 743-752 (2007)
  34. Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Vasilakis N, Fokam EB, Hanson CT, Weinberg E, Sall AA, Whitehead SS, Hanley KA, Weaver SC. Virology 377 296-307 (2008)
  35. Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Steuer C, Gege C, Fischl W, Heinonen KH, Bartenschlager R, Klein CD. Bioorg Med Chem 19 4067-4074 (2011)
  36. Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. Ekonomiuk D, Su XC, Ozawa K, Bodenreider C, Lim SP, Yin Z, Keller TH, Beer D, Patel V, Otting G, Caflisch A, Huang D. PLoS Negl Trop Dis 3 e356 (2009)
  37. Solution conformations of Zika NS2B-NS3pro and its inhibition by natural products from edible plants. Roy A, Lim L, Srivastava S, Lu Y, Song J. PLoS One 12 e0180632 (2017)
  38. Macromolecular assembly-driven processing of the 2/3 cleavage site in the alphavirus replicase polyprotein. Lulla A, Lulla V, Merits A. J Virol 86 553-565 (2012)
  39. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Schüller A, Yin Z, Brian Chia CS, Doan DN, Kim HK, Shang L, Loh TP, Hill J, Vasudevan SG. Antiviral Res 92 96-101 (2011)
  40. Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors. Takahashi H, Takahashi C, Moreland NJ, Chang YT, Sawasaki T, Ryo A, Vasudevan SG, Suzuki Y, Yamamoto N. Antiviral Res 96 305-314 (2012)
  41. Letter Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease. Chen X, Yang K, Wu C, Chen C, Hu C, Buzovetsky O, Wang Z, Ji X, Xiong Y, Yang H. Cell Res 26 1260-1263 (2016)
  42. In-silico screening for anti-Zika virus phytochemicals. Byler KG, Ogungbe IV, Setzer WN. J Mol Graph Model 69 78-91 (2016)
  43. Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. Tiew KC, Dou D, Teramoto T, Lai H, Alliston KR, Lushington GH, Padmanabhan R, Groutas WC. Bioorg Med Chem 20 1213-1221 (2012)
  44. Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. J Gen Virol 89 1010-1014 (2008)
  45. The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. Chernov AV, Shiryaev SA, Aleshin AE, Ratnikov BI, Smith JW, Liddington RC, Strongin AY. J Biol Chem 283 17270-17278 (2008)
  46. Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. Rothan HA, Bahrani H, Rahman NA, Yusof R. BMC Microbiol 14 140 (2014)
  47. A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication. Pambudi S, Kawashita N, Phanthanawiboon S, Omokoko MD, Masrinoul P, Yamashita A, Limkittikul K, Yasunaga T, Takagi T, Ikuta K, Kurosu T. Biochem Biophys Res Commun 440 393-398 (2013)
  48. Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. Nitsche C, Steuer C, Klein CD. Bioorg Med Chem 19 7318-7337 (2011)
  49. The dengue virus NS2B-NS3 protease retains the closed conformation in the complex with BPTI. Chen WN, Loscha KV, Nitsche C, Graham B, Otting G. FEBS Lett 588 2206-2211 (2014)
  50. Unstructural biology of the Dengue virus proteins. Meng F, Badierah RA, Almehdar HA, Redwan EM, Redwan EM, Kurgan L, Uversky VN. FEBS J 282 3368-3394 (2015)
  51. Research Support, Non-U.S. Gov't Binding mode of the activity-modulating C-terminal segment of NS2B to NS3 in the dengue virus NS2B-NS3 protease. de la Cruz L, Chen WN, Graham B, Otting G. FEBS J 281 1517-1533 (2014)
  52. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. Wichapong K, Pianwanit S, Sippl W, Kokpol S. J Mol Recognit 23 283-300 (2010)
  53. Structure-guided fragment-based in silico drug design of dengue protease inhibitors. Knehans T, Schüller A, Doan DN, Nacro K, Hill J, Güntert P, Madhusudhan MS, Weil T, Vasudevan SG. J Comput Aided Mol Des 25 263-274 (2011)
  54. Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase. Shiryaev SA, Cheltsov AV, Gawlik K, Ratnikov BI, Strongin AY. Assay Drug Dev Technol 9 69-78 (2011)
  55. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan. Idrees S, Ashfaq UA. Genet Vaccines Ther 10 6 (2012)
  56. Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold. Aravapalli S, Lai H, Teramoto T, Alliston KR, Lushington GH, Ferguson EL, Padmanabhan R, Groutas WC. Bioorg Med Chem 20 4140-4148 (2012)
  57. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Tomlinson SM, Watowich SJ. Antiviral Res 93 245-252 (2012)
  58. Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. Sweeney NL, Hanson AM, Mukherjee S, Ndjomou J, Geiss BJ, Steel JJ, Frankowski KJ, Li K, Schoenen FJ, Frick DN. ACS Infect Dis 1 140-148 (2015)
  59. Expression and purification of a two-component flaviviral proteinase resistant to autocleavage at the NS2B-NS3 junction region. Shiryaev SA, Aleshin AE, Ratnikov BI, Smith JW, Liddington RC, Strongin AY. Protein Expr Purif 52 334-339 (2007)
  60. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Lai H, Sridhar Prasad G, Padmanabhan R. Antiviral Res 97 74-80 (2013)
  61. Genomics, proteomics and evolution of dengue virus. Dwivedi VD, Tripathi IP, Tripathi RC, Bharadwaj S, Mishra SK. Brief Funct Genomics 16 217-227 (2017)
  62. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease. Su XC, Ozawa K, Yagi H, Lim SP, Wen D, Ekonomiuk D, Huang D, Keller TH, Sonntag S, Caflisch A, Vasudevan SG, Otting G. FEBS J 276 4244-4255 (2009)
  63. Structural characterization of the linked NS2B-NS3 protease of Zika virus. Li Y, Phoo WW, Loh YR, Zhang Z, Ng EY, Wang W, Keller TH, Luo D, Kang C. FEBS Lett 591 2338-2347 (2017)
  64. Design, structure-based focusing and in silico screening of combinatorial library of peptidomimetic inhibitors of Dengue virus NS2B-NS3 protease. Frecer V, Miertus S. J Comput Aided Mol Des 24 195-212 (2010)
  65. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. Melino S, Paci M. FEBS J 274 2986-3002 (2007)
  66. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Ezgimen M, Lai H, Mueller NH, Lee K, Cuny G, Ostrov DA, Padmanabhan R. Antiviral Res 94 18-24 (2012)
  67. Exploring the binding of peptidic West Nile virus NS2B-NS3 protease inhibitors by NMR. Kang C, Gayen S, Wang W, Severin R, Chen AS, Lim HA, Chia CS, Schüller A, Doan DN, Poulsen A, Hill J, Vasudevan SG, Keller TH. Antiviral Res 97 137-144 (2013)
  68. Expression, purification, and initial structural characterization of nonstructural protein 2B, an integral membrane protein of Dengue-2 virus, in detergent micelles. Huang Q, Chen AS, Li Q, Kang C. Protein Expr Purif 80 169-175 (2011)
  69. Generation of pseudocontact shifts in protein NMR spectra with a genetically encoded cobalt(II)-binding amino acid. Nguyen TH, Ozawa K, Stanton-Cook M, Barrow R, Huber T, Otting G. Angew Chem Int Ed Engl 50 692-694 (2011)
  70. Increasing Clinical Severity during a Dengue Virus Type 3 Cuban Epidemic: Deep Sequencing of Evolving Viral Populations. Rodriguez-Roche R, Blanc H, Bordería AV, Díaz G, Henningsson R, Gonzalez D, Santana E, Alvarez M, Castro O, Fontes M, Vignuzzi M, Guzman MG. J Virol 90 4320-4333 (2016)
  71. Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Phong WY, Moreland NJ, Lim SP, Wen D, Paradkar PN, Vasudevan SG. Biosci Rep 31 399-409 (2011)
  72. Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. Prusis P, Junaid M, Petrovska R, Yahorava S, Yahorau A, Katzenmeier G, Lapins M, Wikberg JE. Biochem Biophys Res Commun 434 767-772 (2013)
  73. Endoplasmic Reticulum Protein SCAP Inhibits Dengue Virus NS2B3 Protease by Suppressing Its K27-Linked Polyubiquitylation. Liu H, Zhang L, Sun J, Chen W, Li S, Wang Q, Yu H, Xia Z, Jin X, Wang C. J Virol 91 e02234-16 (2017)
  74. Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease. Lin CW, Huang HD, Shiu SY, Chen WJ, Tsai MH, Huang SH, Wan L, Lin YJ. Virus Res 127 88-94 (2007)
  75. Internally quenched fluorescent peptide libraries with randomized sequences designed to detect endopeptidases. Oliveira LC, Silva VO, Okamoto DN, Kondo MY, Santos SM, Hirata IY, Vallim MA, Pascon RC, Gouvea IE, Juliano MA, Juliano L. Anal Biochem 421 299-307 (2012)
  76. Conservation and variability of West Nile virus proteins. Koo QY, Khan AM, Jung KO, Ramdas S, Miotto O, Tan TW, Brusic V, Salmon J, August JT. PLoS One 4 e5352 (2009)
  77. Direct evidence of a low barrier hydrogen bond in the catalytic triad of a Serine protease. Agback P, Agback T. Sci Rep 8 10078 (2018)
  78. NS3 protease from flavivirus as a target for designing antiviral inhibitors against dengue virus. Natarajan S. Genet Mol Biol 33 214-219 (2010)
  79. Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. Braun NJ, Quek JP, Huber S, Kouretova J, Rogge D, Lang-Henkel H, Cheong EZK, Chew BLA, Heine A, Luo D, Steinmetzer T. ChemMedChem 15 1439-1452 (2020)
  80. Viral proteases: Structure, mechanism and inhibition. Zephyr J, Kurt Yilmaz N, Schiffer CA. Enzymes 50 301-333 (2021)
  81. Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptide. Rothan HA, Mohamed Z, Suhaeb AM, Rahman NA, Yusof R. OMICS 17 560-567 (2013)
  82. Germinal center reaction following cutaneous dengue virus infection in immune-competent mice. Yam-Puc JC, García-Cordero J, Calderón-Amador J, Donis-Maturano L, Cedillo-Barrón L, Flores-Romo L. Front Immunol 6 188 (2015)
  83. Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors. Timiri AK, Selvarasu S, Kesherwani M, Vijayan V, Sinha BN, Devadasan V, Jayaprakash V. Bioorg Chem 62 74-82 (2015)
  84. Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: In silico ligand screening and molecular dynamics studies of inhibition. Mukhametov A, Newhouse EI, Aziz NA, Saito JA, Alam M. J Mol Graph Model 52 103-113 (2014)
  85. Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly. VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC. J Virol 89 8632-8642 (2015)
  86. Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors. Zhou GC, Weng Z, Shao X, Liu F, Nie X, Liu J, Wang D, Wang C, Guo K. Bioorg Med Chem Lett 23 6549-6554 (2013)
  87. Identification of covalent active site inhibitors of dengue virus protease. Koh-Stenta X, Joy J, Wang SF, Kwek PZ, Wee JL, Wan KF, Gayen S, Chen AS, Kang C, Lee MA, Poulsen A, Vasudevan SG, Hill J, Nacro K. Drug Des Devel Ther 9 6389-6399 (2015)
  88. Rational discovery of dengue type 2 non-competitive inhibitors. Heh CH, Othman R, Buckle MJ, Sharifuddin Y, Yusof R, Rahman NA. Chem Biol Drug Des 82 1-11 (2013)
  89. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold. Samanta S, Lim TL, Lam Y. ChemMedChem 8 994-1001 (2013)
  90. Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant West Nile virus NS3. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. Protein Expr Purif 53 87-96 (2007)
  91. Glutarate and N-acetyl-L-glutamate buffers for cell-free synthesis of selectively 15N-labelled proteins. Jia X, Ozawa K, Loscha K, Otting G. J Biomol NMR 44 59-67 (2009)
  92. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Balasubramanian A, Manzano M, Teramoto T, Pilankatta R, Padmanabhan R. Antiviral Res 134 6-16 (2016)
  93. Structure-Based Identification of Natural Products as SARS-CoV-2 Mpro Antagonist from Echinacea angustifolia Using Computational Approaches. Bharadwaj S, El-Kafrawy SA, Alandijany TA, Bajrai LH, Shah AA, Dubey A, Sahoo AK, Yadava U, Kamal MA, Azhar EI, Kang SG, Dwivedi VD. Viruses 13 305 (2021)
  94. Sequence, structure and function relationships in flaviviruses as assessed by evolutive aspects of its conserved non-structural protein domains. da Fonseca NJ, Lima Afonso MQ, Pedersolli NG, de Oliveira LC, Andrade DS, Bleicher L. Biochem Biophys Res Commun 492 565-571 (2017)
  95. Engineering [Ln(DPA)3] 3- binding sites in proteins: a widely applicable method for tagging proteins with lanthanide ions. Jia X, Yagi H, Su XC, Stanton-Cook M, Huber T, Otting G. J Biomol NMR 50 411-420 (2011)
  96. Binding specificity of polypeptide substrates in NS2B/NS3pro serine protease of dengue virus type 2: A molecular dynamics Study. Yotmanee P, Rungrotmongkol T, Wichapong K, Choi SB, Wahab HA, Kungwan N, Hannongbua S. J Mol Graph Model 60 24-33 (2015)
  97. Conformational change study of dengue virus NS2B-NS3 protease using 19F NMR spectroscopy. Zhu L, Yang J, Li H, Sun H, Liu J, Wang J. Biochem Biophys Res Commun 461 677-680 (2015)
  98. Enzymatic analysis of recombinant Japanese encephalitis virus NS2B(H)-NS3pro protease with fluorogenic model peptide substrates. Junaid M, Chalayut C, Sehgelmeble Torrejon A, Angsuthanasombat C, Shutava I, Lapins M, Wikberg JE, Katzenmeier G. PLoS One 7 e36872 (2012)
  99. Functional analysis of potential carboxy-terminal cleavage sites of tick-borne encephalitis virus capsid protein. Schrauf S, Schlick P, Skern T, Mandl CW. J Virol 82 2218-2229 (2008)
  100. Fusion of protegrin-1 and plectasin to MAP30 shows significant inhibition activity against dengue virus replication. Rothan HA, Bahrani H, Mohamed Z, Abd Rahman N, Yusof R. PLoS One 9 e94561 (2014)
  101. Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors. Weng Z, Shao X, Graf D, Wang C, Klein CD, Wang J, Zhou GC. Eur J Med Chem 125 751-759 (2017)
  102. Lyso-myristoyl phosphatidylcholine micelles sustain the activity of Dengue non-structural (NS) protein 3 protease domain fused with the full-length NS2B. Huang Q, Li Q, Joy J, Chen AS, Ruiz-Carrillo D, Hill J, Lescar J, Kang C. Protein Expr Purif 92 156-162 (2013)
  103. Mitochondrial Import of Dengue Virus NS3 Protease and Cleavage of GrpEL1, a Cochaperone of Mitochondrial Hsp70. Gandikota C, Mohammed F, Gandhi L, Maisnam D, Mattam U, Rathore D, Chatterjee A, Mallick K, Billoria A, Prasad VSV, Sepuri NBV, Venkataramana M. J Virol 94 e01178-20 (2020)
  104. Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2. Behnam MAM. Biochimie 182 177-184 (2021)
  105. Small neutral Gd(iii) tags for distance measurements in proteins by double electron-electron resonance experiments. Mahawaththa MC, Lee MD, Giannoulis A, Adams LA, Feintuch A, Swarbrick JD, Graham B, Nitsche C, Goldfarb D, Otting G. Phys Chem Chem Phys 20 23535-23545 (2018)
  106. Research Support, Non-U.S. Gov't Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease. Li L, Basavannacharya C, Chan KW, Shang L, Vasudevan SG, Yin Z. Chem Biol Drug Des 86 255-264 (2015)
  107. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 1,3,4,5-tetrasubstituted 1H-pyrrol-2(5H)-one scaffold. Gao Y, Samanta S, Cui T, Lam Y. ChemMedChem 8 1554-1560 (2013)
  108. Using a genetically encoded fluorescent amino acid as a site-specific probe to detect binding of low-molecular-weight compounds. Ugwumba IN, Ozawa K, de la Cruz L, Xu ZQ, Herlt AJ, Hadler KS, Coppin C, Brown SE, Schenk G, Oakeshott JG, Otting G. Assay Drug Dev Technol 9 50-57 (2011)
  109. Catching a Moving Target: Comparative Modeling of Flaviviral NS2B-NS3 Reveals Small Molecule Zika Protease Inhibitors. Pach S, Sarter TM, Yousef R, Schaller D, Bergemann S, Arkona C, Rademann J, Nitsche C, Wolber G. ACS Med Chem Lett 11 514-520 (2020)
  110. Flavivirus enzymes and their inhibitors. Knyazhanskaya E, Morais MC, Choi KH. Enzymes 49 265-303 (2021)
  111. High-Throughput Fluorescent Assay for Inhibitor Screening of Proteases from RNA Viruses. Cihlova B, Huskova A, Böserle J, Nencka R, Boura E, Silhan J. Molecules 26 3792 (2021)
  112. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection. Pathak N, Lai ML, Chen WY, Hsieh BW, Yu GY, Yang JM. BMC Bioinformatics 18 548 (2017)
  113. Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice. Lee HC, Yen YT, Chen WY, Wu-Hsieh BA, Wu SC. PLoS One 6 e25800 (2011)
  114. Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus. Kelly EP, Polo S, Sun W, Falgout B. Virus Genes 43 18-26 (2011)
  115. Reaction mechanism of the dengue virus serine protease: a QM/MM study. Lima MC, Seabra GM. Phys Chem Chem Phys 18 30288-30296 (2016)
  116. Uncoupling of Protease trans-Cleavage and Helicase Activities in Pestivirus NS3. Zheng F, Lu G, Li L, Gong P, Pan Z. J Virol 91 e01094-17 (2017)
  117. In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus. Li Z, Xu J, Lang Y, Wu X, Hu S, Samrat SK, Tharappel AM, Kuo L, Butler D, Song Y, Zhang QY, Zhou J, Li H. Acta Pharm Sin B 12 1662-1670 (2022)
  118. Antiviral potential of 4-hydroxypanduratin A, secondary metabolite of Fingerroot, Boesenbergia pandurata (Schult.), towards Japanese Encephalitis virus NS2B/NS3 protease. Seniya C, Mishra H, Yadav A, Sagar N, Chaturvedi B, Uchadia K, Wadhwa G. Bioinformation 9 54-60 (2013)
  119. Discovery of Bispecific Lead Compounds from Azadirachta indica against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations. Kumar S, El-Kafrawy SA, Bharadwaj S, Maitra SS, Alandijany TA, Faizo AA, Khateb AM, Dwivedi VD, Azhar EI. Molecules 27 2562 (2022)
  120. Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds. de Oliveira AS, Gazolla PAR, Oliveira AFCDS, Pereira WL, de S Viol LC, Maia AFDS, Santos EG, da Silva ÍEP, Mendes TAO, da Silva AM, Dias RS, da Silva CC, Polêto MD, Teixeira RR, de Paula SO. PLoS One 14 e0223017 (2019)
  121. Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9,10-dihydro-3H,4aH-1,3,9,10a-tetraazaphenanthren-4-one scaffold. Samanta S, Cui T, Lam Y. ChemMedChem 7 1210-1216 (2012)
  122. NS2B/NS3 protease: allosteric effect of mutations associated with the pathogenicity of tick-borne encephalitis virus. Potapova UV, Feranchuk SI, Potapov VV, Kulakova NV, Kondratov IG, Leonova GN, Belikov SI. J Biomol Struct Dyn 30 638-651 (2012)
  123. Phosphonate inhibitors of West Nile virus NS2B/NS3 protease. Skoreński M, Milewska A, Pyrć K, Sieńczyk M, Oleksyszyn J. J Enzyme Inhib Med Chem 34 8-14 (2019)
  124. Structure and sequence based functional annotation of Zika virus NS2b protein: Computational insights. Aguilera-Pesantes D, Méndez MA. Biochem Biophys Res Commun 492 659-667 (2017)
  125. Tick-Borne Encephalitis Virus Adaptation in Different Host Environments and Existence of Quasispecies. Helmová R, Hönig V, Tykalová H, Palus M, Bell-Sakyi L, Grubhoffer L. Viruses 12 E902 (2020)
  126. West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy. Gayen S, Chen AS, Huang Q, Kang C. Biochem Biophys Res Commun 423 799-804 (2012)
  127. Yellow fever virus NS2B/NS3 protease: hydrolytic properties and substrate specificity. Kondo MY, Oliveira LC, Okamoto DN, de Araujo MR, Duarte dos Santos CN, Juliano MA, Juliano L, Gouvea IE. Biochem Biophys Res Commun 407 640-644 (2011)
  128. An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection. Acharya D, Bai F. Methods Mol Biol 1435 249-291 (2016)
  129. Biochemical characterisation of Murray Valley encephalitis virus proteinase. Joy J, Mee NF, Kuan WL, Perlyn KZ, Wen TS, Hill J. FEBS Lett 584 3149-3152 (2010)
  130. Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design. Aguilera-Pesantes D, Robayo LE, Méndez PE, Mollocana D, Marrero-Ponce Y, Torres FJ, Méndez MA. Biochem Biophys Res Commun 492 631-642 (2017)
  131. Mechanism through Which Retrocyclin Targets Flavivirus Multiplication. Jia X, Guo J, Yuan W, Sun L, Liu Y, Zhou M, Xiao G, Lu W, Garzino-Demo A, Wang W. J Virol 95 e0056021 (2021)
  132. The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase. Shiryaev SA, Chernov AV, Shiryaeva TN, Aleshin AE, Strongin AY. Arch Virol 156 313-318 (2011)
  133. Broad-spectrum catalytic metallopeptide inactivators of Zika and West Nile virus NS2B/NS3 proteases. Pinkham AM, Yu Z, Cowan JA. Chem Commun (Camb) 54 12357-12360 (2018)
  134. Ethyl 4-(4-methylphenyl)-4-pentenoate from Vetiveria zizanioides Inhibits Dengue NS2B-NS3 Protease and Prevents Viral Assembly: A Computational Molecular Dynamics and Docking Study. Lavanya P, Ramaiah S, Anbarasu A. Cell Biochem Biophys 74 337-351 (2016)
  135. Mapping of molecular interactions between human E3 ligase TRIM69 and Dengue virus NS3 protease using hydrogen-deuterium exchange mass spectrometry. Bagga T, Tulsian NK, Mok YK, Kini RM, Sivaraman J. Cell Mol Life Sci 79 233 (2022)
  136. TRAF6 Plays a Proviral Role in Tick-Borne Flavivirus Infection through Interaction with the NS3 Protease. Youseff BH, Brewer TG, McNally KL, Izuogu AO, Lubick KJ, Presloid JB, Alqahtani S, Chattopadhyay S, Best SM, Hu X, Taylor RT. iScience 15 489-501 (2019)
  137. The Dengue virus protease NS2B3 cleaves cyclic GMP-AMP synthase to suppress cGAS activation. Bhattacharya M, Bhowmik D, Tian Y, He H, Zhu F, Yin Q. J Biol Chem 299 102986 (2023)
  138. A virus becomes a global concern: research activities on West-Nile virus. Klingelhöfer D, Braun M, Kramer IM, Reuss F, Müller R, Groneberg DA, Brüggmann D. Emerg Microbes Infect 12 2256424 (2023)
  139. An inhibition model of BPTI to unlinked dengue virus NS2B-NS3 protease. Li H, Zhu L, Hou S, Yang J, Wang J, Liu J. FEBS Lett 588 2794-2799 (2014)
  140. Autocatalytic activation of a malarial egress protease is druggable and requires a protein cofactor. Tan MSY, Koussis K, Withers-Martinez C, Howell SA, Thomas JA, Hackett F, Knuepfer E, Shen M, Hall MD, Snijders AP, Blackman MJ. EMBO J 40 e107226 (2021)
  141. Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence. Piccirillo E, Merget B, Sotriffer CA, do Amaral AT. J Comput Aided Mol Des 30 251-270 (2016)
  142. Discovery of New Zika Protease and Polymerase Inhibitors through the Open Science Collaboration Project OpenZika. Mottin M, de Paula Sousa BK, de Moraes Roso Mesquita NC, de Oliveira KIZ, Noske GD, Sartori GR, de Oliveira Albuquerque A, Urbina F, Puhl AC, Moreira-Filho JT, Souza GE, Guido RVC, Muratov E, Neves BJ, Martins da Silva JH, Clark AE, Siqueira-Neto JL, Perryman AL, Oliva G, Ekins S, Andrade CH. J Chem Inf Model 62 6825-6843 (2022)
  143. Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus. Shiryaev SA, Radichev IA, Ratnikov BI, Aleshin AE, Gawlik K, Stec B, Frisch C, Knappik A, Strongin AY. Biochem J 427 369-376 (2010)
  144. Mutagenesis of D80-82 and G83 residues in West Nile Virus NS2B: effects on NS2B-NS3 activity and viral replication. Jia F, Fan J, Zhang B, Yuan Z. Virol Sin 28 16-23 (2013)
  145. Riboflavin, a Potent Neuroprotective Vitamin: Focus on Flavivirus and Alphavirus Proteases. Eberle RJ, Olivier DS, Amaral MS, Pacca CC, Nogueira ML, Arni RK, Willbold D, Coronado MA. Microorganisms 10 1331 (2022)
  146. Varying structural motifs in the salen based metal complexes of Co(ii), Ni(ii) and Cu(ii): synthesis, crystal structures, molecular dynamics and biological activities. Saini AK, Kumari P, Sharma V, Mathur P, Mobin SM. Dalton Trans 45 19096-19108 (2016)
  147. A competition smFRET assay to study ligand-induced conformational changes of the dengue virus protease. Maus H, Hinze G, Hammerschmidt SJ, Basché T, Schirmeister T. Protein Sci 32 e4526 (2023)
  148. Computational study of nitro-benzylidene phenazine as dengue virus-2 NS2B-NS3 protease inhibitor. Salin NH, Hariono M, Khalili NSD, Zakaria II, Saqallah FG, Mohamad Taib MNA, Kamarulzaman EE, Wahab HA, Khawory MH. Front Mol Biosci 9 875424 (2022)
  149. Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease. Uday RVS, Misra R, Harika A, Dolui S, Saha A, Pal U, Ravichandiran V, Maiti NC. PLoS One 16 e0257206 (2021)
  150. Design, synthesis, in vitro, in silico, and SAR studies of flavone analogs towards anti-dengue activity. Patigo A, Hengphasatporn K, Cao V, Paunrat W, Vijara N, Chokmahasarn T, Maitarad P, Rungrotmongkol T, Shigeta Y, Boonyasuppayakorn S, Khotavivattana T. Sci Rep 12 21646 (2022)
  151. Dynamic Interactions of Post Cleaved NS2B Cofactor and NS3 Protease Identified by Integrative Structural Approaches. Quek JP, Ser Z, Chew BLA, Li X, Wang L, Sobota RM, Luo D, Phoo WW. Viruses 14 1440 (2022)
  152. Identification and In Silico Binding Study of a Highly Potent DENV NS2B-NS3 Covalent Inhibitor. Lin X, Cheng J, Wu Y, Zhang Y, Jiang H, Wang J, Wang X, Cheng M. ACS Med Chem Lett 13 599-607 (2022)
  153. Myricetin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting the Active and Locking the Inactive Conformations. Dang M, Lim L, Roy A, Song J. ACS Omega 7 2798-2808 (2022)
  154. NS2B/3 proteolysis at the C-prM junction of the tick-borne encephalitis virus polyprotein is highly membrane dependent. Kurz M, Stefan N, Zhu J, Skern T. Virus Res 168 48-55 (2012)
  155. Probing contacts of inhibitor locked in transition states in the catalytic triad of DENV2 type serine protease and its mutants by 1H, 19F and 15 N NMR spectroscopy. Agback P, Woestenenk E, Agback T. BMC Mol Cell Biol 21 38 (2020)
  156. Transplantation of a hydrogen bonding network from West Nile virus protease onto Dengue-2 protease improves catalytic efficiency and sheds light on substrate specificity. Doan DN, Li KQ, Basavannacharya C, Vasudevan SG, Madhusudhan MS. Protein Eng Des Sel 25 843-850 (2012)
  157. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors. Luo PH, Zhang XR, Huang L, Yuan L, Zhou XZ, Gao X, Li LS. J Recept Signal Transduct Res 37 481-492 (2017)
  158. Letter Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases. Jones CL, Yeung BK, Manjunatha U, Shi PY, Bodenreider C, Diagana TT. Nat Rev Drug Discov 14 442-444 (2015)
  159. Drugs to limit Zika virus infection and implication for maternal-fetal health. Kumar A, Kumar D, Jose J, Giri R, Mysorekar IU. Front Virol 2 928599 (2022)
  160. Mass Spectrometry versus Conventional Techniques of Protein Detection: Zika Virus NS3 Protease Activity towards Cellular Proteins. Dabrowska A, Milewska A, Ner-Kluza J, Suder P, Pyrc K. Molecules 26 3732 (2021)
  161. Mutation and docking studies on NS2b-NS3 complex from yellow fever virus towards drug discovery. Kannappan P, Narayanan S. Bioinformation 6 303-306 (2011)
  162. Potential Dual Role of West Nile Virus NS2B in Orchestrating NS3 Enzymatic Activity in Viral Replication. Tseng AC, Nerurkar VR, Neupane KR, Kae H, Kaufusi PH. Viruses 13 216 (2021)
  163. Targeting PKC-β II by Peptides and Peptidomimetics Derived from RACK 1: An In Silico Approach. Jain K, Sobhia ME. Mol Inform 30 45-62 (2011)
  164. The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase. Boonyasuppayakorn S, Saelee T, Huynh TNT, Hairani R, Hengphasatporn K, Loeanurit N, Cao V, Vibulakhaophan V, Siripitakpong P, Kaur P, Chu JJH, Tunghirun C, Choksupmanee O, Chimnaronk S, Shigeta Y, Rungrotmongkol T, Chavasiri W. Sci Rep 13 4891 (2023)
  165. The reaction mechanism of Zika virus NS2B/NS3 serine protease inhibition by dipeptidyl aldehyde: a QM/MM study. Nutho B, Mulholland AJ, Rungrotmongkol T. Phys Chem Chem Phys 21 14945-14956 (2019)
  166. Acetylation of the NS3 helicase by KAT5γ is essential for flavivirus replication. Serman T, Chiang C, Liu G, Sayyad Z, Pandey S, Volcic M, Lee H, Muppala S, Acharya D, Goins C, Stauffer SR, Sparrer KMJ, Gack MU. Cell Host Microbe 31 1317-1330.e10 (2023)
  167. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. Zephyr J, Rao DN, Johnson C, Shaqra AM, Nalivaika EA, Jordan A, Kurt Yilmaz N, Ali A, Schiffer CA. Bioorg Chem 131 106269 (2023)
  168. Anti-dengue drug: viral polyprotein, a potential target. Mahmood SU, Mushtaq M, Syed MJ. Drug Des Devel Ther 10 2047-2048 (2016)
  169. Cationic Geminoid Peptide Amphiphiles Inhibit DENV2 Protease, Furin, and Viral Replication. Damen M, Izidoro MA, Okamoto DN, Oliveira LCG, Amatdjais-Groenen HIV, van Dongen SFM, van Cleef KWR, van Rij RP, Dieteren CEJ, Gironés D, van Buuren BNM, Martina BEE, Osterhaus ADME, Juliano L, Scholte BJ, Feiters MC. Molecules 27 3217 (2022)
  170. Design, Synthesis, and in-vitro Protease Inhibition Assay of Linear Pentapeptides as Potential Dengue Virus NS2B/NS3 Protease Inhibitors. Abdalsatar Abdalrazaq N, Ezleen Binti Kamarulzaman E. Arch Razi Inst 77 843-852 (2022)
  171. Designing photoaffinity tool compounds for the investigation of the DENV NS2B-NS3 protease allosteric binding pocket. Maus H, Gellert A, Englert OR, Chen JX, Schirmeister T, Barthels F. RSC Med Chem 14 2365-2379 (2023)
  172. Exploring the viral protease inhibitor space driven by consensus scoring-based virtual screening. Mushtaq M, Naz S, Ashraf S, Doerksen RJ, Nur-E-Alam M, Ul-Haq Z. In Silico Pharmacol 12 2 (2024)
  173. Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals. Schroeder B, Demirel P, Fischer C, Masri E, Kallis S, Redl L, Rudolf T, Bergemann S, Arkona C, Nitsche C, Bartenschlager R, Rademann J. ACS Med Chem Lett 12 1955-1961 (2021)
  174. Novel Aporphine- and Proaporphine-Clerodane Hybrids Identified from the Barks of Taiwanese Polyalthia longifolia (Sonn.) Thwaites var. pendula with Strong Anti-DENV2 Activity. Lo IW, Liao GY, Lee JC, Chang CI, Wu YC, Chen YY, Liu SP, Su HJ, Liu CI, Kuo CY, Lin ZY, Li TL, Lin YS, Liaw CC. Pharmaceuticals (Basel) 15 1218 (2022)
  175. Optimized sequential purification protocol for in vivo site-specific biotinylated full-length dengue virus capsid protein. Chong MK, Parthasarathy K, Yeo HY, Ng ML. Protein Eng Des Sel 26 377-387 (2013)
  176. Packaging defects in pestiviral NS4A can be compensated by mutations in NS2 and NS3. Fellenberg J, Dubrau D, Isken O, Tautz N. J Virol 97 e0057223 (2023)


Quick links